Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM a...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2022-04, Vol.157 (2), p.249-269 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 2 |
| container_start_page | 249 |
| container_title | Journal of neuro-oncology |
| container_volume | 157 |
| creator | Mills, Matthew N. King, Whitney Soyano, Aixa Pina, Yolanda Czerniecki, Brian J. Forsyth, Peter A. Soliman, Hatem Han, Hyo S. Ahmed, Kamran A. |
| description | Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM and LMD. However, the optimal management of these cases is rapidly evolving and requires a multidisciplinary approach. Herein, a team of radiation oncologists, medical oncologists, neuro-oncologists, and breast surgeon created a review of the evolving management of HER2-positive BCBM and LMD. We assess the epidemiology, diagnosis, and evolving treatment options for patients with HER2-positive BCBM and LMD, as well as the ongoing prospective clinical trials enrolling these patients. The management of HER2-positive BCBM and LMD represents an increasingly common challenge that involves the coordination of local and systemic therapy. Advances in systemic therapy have resulted in an improved prognosis, and promising targeted therapies currently under prospective investigation have the potential to further benefit these patients. |
| doi_str_mv | 10.1007/s11060-022-03977-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2636148039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2652732468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-75ee59d9f3f88da2e4b32b639e7662ae98ce313c7aebb0ab916fa0f12580b6f83</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobn78AS8k4I0g1SSnSdpLGdMJA0FUvAtpezo6-jGTbsx_b-amghdehZPzvG_CQ8gZZ9ecMX3jOWeKRUyIiEGqdbTeI0MuNUQaNOyTIeNKRzKN3wbkyPs5YyzWwA_JAKSI4wTkkLyOV129qtoZbWxrZ9hg29OupJPxk7iimUPre5rbNkcXJlu1tME-3FmPntq2oDUu-i6kQgXamhaVDxE8IQelrT2e7s5j8nI3fh5Nounj_cPodhrloGUfaYko0yItoUySwgqMMxCZghS1UsJimuQIHHJtMcuYzVKuSstKLmTCMlUmcEwut70L170v0femqXyOdW1b7JbeCAWKx0nQE9CLP-i8W7o2_C5QUmgQsdoUii2Vu857h6VZuKqx7sNwZjbWzda6CdbNl3WzDqHzXfUya7D4iXxrDgBsAR9WQZT7ffuf2k-_fo2X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2652732468</pqid></control><display><type>article</type><title>Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mills, Matthew N. ; King, Whitney ; Soyano, Aixa ; Pina, Yolanda ; Czerniecki, Brian J. ; Forsyth, Peter A. ; Soliman, Hatem ; Han, Hyo S. ; Ahmed, Kamran A.</creator><creatorcontrib>Mills, Matthew N. ; King, Whitney ; Soyano, Aixa ; Pina, Yolanda ; Czerniecki, Brian J. ; Forsyth, Peter A. ; Soliman, Hatem ; Han, Hyo S. ; Ahmed, Kamran A.</creatorcontrib><description>Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM and LMD. However, the optimal management of these cases is rapidly evolving and requires a multidisciplinary approach. Herein, a team of radiation oncologists, medical oncologists, neuro-oncologists, and breast surgeon created a review of the evolving management of HER2-positive BCBM and LMD. We assess the epidemiology, diagnosis, and evolving treatment options for patients with HER2-positive BCBM and LMD, as well as the ongoing prospective clinical trials enrolling these patients. The management of HER2-positive BCBM and LMD represents an increasingly common challenge that involves the coordination of local and systemic therapy. Advances in systemic therapy have resulted in an improved prognosis, and promising targeted therapies currently under prospective investigation have the potential to further benefit these patients.</description><identifier>ISSN: 0167-594X</identifier><identifier>ISSN: 1573-7373</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-022-03977-x</identifier><identifier>PMID: 35244835</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Brain cancer ; Brain Neoplasms - metabolism ; Breast cancer ; Breast Neoplasms - metabolism ; Cancer therapies ; Clinical trials ; Epidemiology ; Epidermal growth factor ; ErbB-2 protein ; Female ; Humans ; Medical prognosis ; Medicine ; Medicine & Public Health ; Meningeal Neoplasms - therapy ; Meninges ; Metastases ; Metastasis ; Neurology ; Oncology ; Patients ; Prognosis ; Prospective Studies ; Receptor, ErbB-2 - metabolism ; Topic Review</subject><ispartof>Journal of neuro-oncology, 2022-04, Vol.157 (2), p.249-269</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-75ee59d9f3f88da2e4b32b639e7662ae98ce313c7aebb0ab916fa0f12580b6f83</citedby><cites>FETCH-LOGICAL-c375t-75ee59d9f3f88da2e4b32b639e7662ae98ce313c7aebb0ab916fa0f12580b6f83</cites><orcidid>0000-0003-3331-1529</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-022-03977-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-022-03977-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35244835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mills, Matthew N.</creatorcontrib><creatorcontrib>King, Whitney</creatorcontrib><creatorcontrib>Soyano, Aixa</creatorcontrib><creatorcontrib>Pina, Yolanda</creatorcontrib><creatorcontrib>Czerniecki, Brian J.</creatorcontrib><creatorcontrib>Forsyth, Peter A.</creatorcontrib><creatorcontrib>Soliman, Hatem</creatorcontrib><creatorcontrib>Han, Hyo S.</creatorcontrib><creatorcontrib>Ahmed, Kamran A.</creatorcontrib><title>Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM and LMD. However, the optimal management of these cases is rapidly evolving and requires a multidisciplinary approach. Herein, a team of radiation oncologists, medical oncologists, neuro-oncologists, and breast surgeon created a review of the evolving management of HER2-positive BCBM and LMD. We assess the epidemiology, diagnosis, and evolving treatment options for patients with HER2-positive BCBM and LMD, as well as the ongoing prospective clinical trials enrolling these patients. The management of HER2-positive BCBM and LMD represents an increasingly common challenge that involves the coordination of local and systemic therapy. Advances in systemic therapy have resulted in an improved prognosis, and promising targeted therapies currently under prospective investigation have the potential to further benefit these patients.</description><subject>Brain cancer</subject><subject>Brain Neoplasms - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Epidemiology</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningeal Neoplasms - therapy</subject><subject>Meninges</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Topic Review</subject><issn>0167-594X</issn><issn>1573-7373</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kF1LwzAUhoMobn78AS8k4I0g1SSnSdpLGdMJA0FUvAtpezo6-jGTbsx_b-amghdehZPzvG_CQ8gZZ9ecMX3jOWeKRUyIiEGqdbTeI0MuNUQaNOyTIeNKRzKN3wbkyPs5YyzWwA_JAKSI4wTkkLyOV129qtoZbWxrZ9hg29OupJPxk7iimUPre5rbNkcXJlu1tME-3FmPntq2oDUu-i6kQgXamhaVDxE8IQelrT2e7s5j8nI3fh5Nounj_cPodhrloGUfaYko0yItoUySwgqMMxCZghS1UsJimuQIHHJtMcuYzVKuSstKLmTCMlUmcEwut70L170v0femqXyOdW1b7JbeCAWKx0nQE9CLP-i8W7o2_C5QUmgQsdoUii2Vu857h6VZuKqx7sNwZjbWzda6CdbNl3WzDqHzXfUya7D4iXxrDgBsAR9WQZT7ffuf2k-_fo2X</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Mills, Matthew N.</creator><creator>King, Whitney</creator><creator>Soyano, Aixa</creator><creator>Pina, Yolanda</creator><creator>Czerniecki, Brian J.</creator><creator>Forsyth, Peter A.</creator><creator>Soliman, Hatem</creator><creator>Han, Hyo S.</creator><creator>Ahmed, Kamran A.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3331-1529</orcidid></search><sort><creationdate>20220401</creationdate><title>Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease</title><author>Mills, Matthew N. ; King, Whitney ; Soyano, Aixa ; Pina, Yolanda ; Czerniecki, Brian J. ; Forsyth, Peter A. ; Soliman, Hatem ; Han, Hyo S. ; Ahmed, Kamran A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-75ee59d9f3f88da2e4b32b639e7662ae98ce313c7aebb0ab916fa0f12580b6f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brain cancer</topic><topic>Brain Neoplasms - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Epidemiology</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningeal Neoplasms - therapy</topic><topic>Meninges</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Topic Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mills, Matthew N.</creatorcontrib><creatorcontrib>King, Whitney</creatorcontrib><creatorcontrib>Soyano, Aixa</creatorcontrib><creatorcontrib>Pina, Yolanda</creatorcontrib><creatorcontrib>Czerniecki, Brian J.</creatorcontrib><creatorcontrib>Forsyth, Peter A.</creatorcontrib><creatorcontrib>Soliman, Hatem</creatorcontrib><creatorcontrib>Han, Hyo S.</creatorcontrib><creatorcontrib>Ahmed, Kamran A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mills, Matthew N.</au><au>King, Whitney</au><au>Soyano, Aixa</au><au>Pina, Yolanda</au><au>Czerniecki, Brian J.</au><au>Forsyth, Peter A.</au><au>Soliman, Hatem</au><au>Han, Hyo S.</au><au>Ahmed, Kamran A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>157</volume><issue>2</issue><spage>249</spage><epage>269</epage><pages>249-269</pages><issn>0167-594X</issn><issn>1573-7373</issn><eissn>1573-7373</eissn><abstract>Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM and LMD. However, the optimal management of these cases is rapidly evolving and requires a multidisciplinary approach. Herein, a team of radiation oncologists, medical oncologists, neuro-oncologists, and breast surgeon created a review of the evolving management of HER2-positive BCBM and LMD. We assess the epidemiology, diagnosis, and evolving treatment options for patients with HER2-positive BCBM and LMD, as well as the ongoing prospective clinical trials enrolling these patients. The management of HER2-positive BCBM and LMD represents an increasingly common challenge that involves the coordination of local and systemic therapy. Advances in systemic therapy have resulted in an improved prognosis, and promising targeted therapies currently under prospective investigation have the potential to further benefit these patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35244835</pmid><doi>10.1007/s11060-022-03977-x</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0003-3331-1529</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2022-04, Vol.157 (2), p.249-269 |
| issn | 0167-594X 1573-7373 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2636148039 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Brain cancer Brain Neoplasms - metabolism Breast cancer Breast Neoplasms - metabolism Cancer therapies Clinical trials Epidemiology Epidermal growth factor ErbB-2 protein Female Humans Medical prognosis Medicine Medicine & Public Health Meningeal Neoplasms - therapy Meninges Metastases Metastasis Neurology Oncology Patients Prognosis Prospective Studies Receptor, ErbB-2 - metabolism Topic Review |
| title | Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A52%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolving%20management%20of%20HER2+%20breast%20cancer%20brain%20metastases%20and%20leptomeningeal%20disease&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Mills,%20Matthew%20N.&rft.date=2022-04-01&rft.volume=157&rft.issue=2&rft.spage=249&rft.epage=269&rft.pages=249-269&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-022-03977-x&rft_dat=%3Cproquest_cross%3E2652732468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2652732468&rft_id=info:pmid/35244835&rfr_iscdi=true |